Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian Peninsula: Comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras

Roshan Koul, Alexander Chacko, Riaz Ahmed, Thomas Varghese, Hashim Javed, Zakia Al-Lamki

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A prospective study of Guillain-Barré syndrome from January 1992 to December 2001 was undertaken. Intravenous immunoglobulins were used in all patients. All patients were followed up until complete recovery. Various parameters, such as onset of weakness, duration of hospital stay, ventilation requirement, residual deficit, and mortality, were recorded. Acute relapses and fluctuations were also noted. The pattern of this group was compared with patients before 1992, who were not given intravenous immunoglobulins in the Sultanate of Oman. Our data were compared with a few studies prior to 1992 from the medical literature. Our study revealed a definite benefit with intravenous immunoglobulins. The disease course and hospital stay were shortened. Fewer patients needed ventilation. There was no mortality, and the residual deficit was less than 5%. Occasional relapses at a later stage in the course of illness have been noted in acute Guillain-Barré syndrome. However, acute relapse, a new phenomenon that was not seen in the pre-intravenous immunoglobulin era, stood at 11.9%. Intravenous immunoglobulins have made a significant difference in the outcome of Guillain-Barré syndrome, but one has to be aware of acute relapses, which usually occur in the first 2 to 3 weeks after administration.

Original languageEnglish
Pages (from-to)767-771
Number of pages5
JournalJournal of Child Neurology
Volume18
Issue number11
Publication statusPublished - Nov 2003

Fingerprint

Intravenous Immunoglobulins
Prospective Studies
Recurrence
Ventilation
Length of Stay
Oman
Mortality

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

@article{19b252123d8f4ceba434c512b67c578a,
title = "Ten-year prospective study (clinical spectrum) of childhood Guillain-Barr{\'e} syndrome in the Arabian Peninsula: Comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras",
abstract = "A prospective study of Guillain-Barr{\'e} syndrome from January 1992 to December 2001 was undertaken. Intravenous immunoglobulins were used in all patients. All patients were followed up until complete recovery. Various parameters, such as onset of weakness, duration of hospital stay, ventilation requirement, residual deficit, and mortality, were recorded. Acute relapses and fluctuations were also noted. The pattern of this group was compared with patients before 1992, who were not given intravenous immunoglobulins in the Sultanate of Oman. Our data were compared with a few studies prior to 1992 from the medical literature. Our study revealed a definite benefit with intravenous immunoglobulins. The disease course and hospital stay were shortened. Fewer patients needed ventilation. There was no mortality, and the residual deficit was less than 5{\%}. Occasional relapses at a later stage in the course of illness have been noted in acute Guillain-Barr{\'e} syndrome. However, acute relapse, a new phenomenon that was not seen in the pre-intravenous immunoglobulin era, stood at 11.9{\%}. Intravenous immunoglobulins have made a significant difference in the outcome of Guillain-Barr{\'e} syndrome, but one has to be aware of acute relapses, which usually occur in the first 2 to 3 weeks after administration.",
author = "Roshan Koul and Alexander Chacko and Riaz Ahmed and Thomas Varghese and Hashim Javed and Zakia Al-Lamki",
year = "2003",
month = "11",
language = "English",
volume = "18",
pages = "767--771",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian Peninsula

T2 - Comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras

AU - Koul, Roshan

AU - Chacko, Alexander

AU - Ahmed, Riaz

AU - Varghese, Thomas

AU - Javed, Hashim

AU - Al-Lamki, Zakia

PY - 2003/11

Y1 - 2003/11

N2 - A prospective study of Guillain-Barré syndrome from January 1992 to December 2001 was undertaken. Intravenous immunoglobulins were used in all patients. All patients were followed up until complete recovery. Various parameters, such as onset of weakness, duration of hospital stay, ventilation requirement, residual deficit, and mortality, were recorded. Acute relapses and fluctuations were also noted. The pattern of this group was compared with patients before 1992, who were not given intravenous immunoglobulins in the Sultanate of Oman. Our data were compared with a few studies prior to 1992 from the medical literature. Our study revealed a definite benefit with intravenous immunoglobulins. The disease course and hospital stay were shortened. Fewer patients needed ventilation. There was no mortality, and the residual deficit was less than 5%. Occasional relapses at a later stage in the course of illness have been noted in acute Guillain-Barré syndrome. However, acute relapse, a new phenomenon that was not seen in the pre-intravenous immunoglobulin era, stood at 11.9%. Intravenous immunoglobulins have made a significant difference in the outcome of Guillain-Barré syndrome, but one has to be aware of acute relapses, which usually occur in the first 2 to 3 weeks after administration.

AB - A prospective study of Guillain-Barré syndrome from January 1992 to December 2001 was undertaken. Intravenous immunoglobulins were used in all patients. All patients were followed up until complete recovery. Various parameters, such as onset of weakness, duration of hospital stay, ventilation requirement, residual deficit, and mortality, were recorded. Acute relapses and fluctuations were also noted. The pattern of this group was compared with patients before 1992, who were not given intravenous immunoglobulins in the Sultanate of Oman. Our data were compared with a few studies prior to 1992 from the medical literature. Our study revealed a definite benefit with intravenous immunoglobulins. The disease course and hospital stay were shortened. Fewer patients needed ventilation. There was no mortality, and the residual deficit was less than 5%. Occasional relapses at a later stage in the course of illness have been noted in acute Guillain-Barré syndrome. However, acute relapse, a new phenomenon that was not seen in the pre-intravenous immunoglobulin era, stood at 11.9%. Intravenous immunoglobulins have made a significant difference in the outcome of Guillain-Barré syndrome, but one has to be aware of acute relapses, which usually occur in the first 2 to 3 weeks after administration.

UR - http://www.scopus.com/inward/record.url?scp=0346734296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346734296&partnerID=8YFLogxK

M3 - Article

C2 - 14696904

AN - SCOPUS:0346734296

VL - 18

SP - 767

EP - 771

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 11

ER -